{"id":"her3-dxd","safety":{"commonSideEffects":[{"rate":"30%","effect":"Nausea"},{"rate":"25%","effect":"Fatigue"},{"rate":"20%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL5095384","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"HER3-DXd works by binding to the HER3 receptor and delivering a cytotoxic payload to cancer cells that overexpress HER3.","oneSentence":"HER3-DXd is a HER3-targeting antibody-drug conjugate.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:33:50.834Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Breast cancer"},{"name":"Gastric cancer"}]},"trialDetails":[{"nctId":"NCT06941272","phase":"PHASE1, PHASE2","title":"A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-05-26","conditions":"Malignant Neoplasm","enrollment":50},{"nctId":"NCT07060807","phase":"PHASE3","title":"A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-21","conditions":"Breast Neoplasms","enrollment":1000},{"nctId":"NCT06469944","phase":"PHASE1, PHASE2","title":"Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-09-20","conditions":"Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms","enrollment":160},{"nctId":"NCT06445972","phase":"PHASE1, PHASE2","title":"Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-08-07","conditions":"Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms","enrollment":210},{"nctId":"NCT04165070","phase":"PHASE1, PHASE2","title":"KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-12-19","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":450},{"nctId":"NCT07286149","phase":"PHASE1, PHASE2","title":"A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-03-23","conditions":"Lung Neoplasm Malignant","enrollment":190},{"nctId":"NCT06596694","phase":"PHASE1, PHASE2","title":"Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-11-03","conditions":"Gastrointestinal Cancer","enrollment":180},{"nctId":"NCT06797635","phase":"PHASE2","title":"Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-20","conditions":"Breast Neoplasms, Breast Cancer","enrollment":372},{"nctId":"NCT05865990","phase":"PHASE2","title":"HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedSIR","startDate":"2023-11-24","conditions":"Metastatic Breast Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Solid Tumor, Adult","enrollment":63},{"nctId":"NCT03260491","phase":"PHASE1","title":"U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2017-10-30","conditions":"Non-Small Cell Lung Cancer (NSCLC)","enrollment":312},{"nctId":"NCT06731907","phase":"PHASE2","title":"A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-30","conditions":"Non-small Cell Lung Cancer","enrollment":90},{"nctId":"NCT06686394","phase":"PHASE1, PHASE2","title":"Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-02-26","conditions":"Breast Neoplasms, Breast Cancer","enrollment":81},{"nctId":"NCT06172478","phase":"PHASE2","title":"A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2024-02-26","conditions":"Advanced Solid Tumor, Melanoma, Head and Neck Cancer","enrollment":740},{"nctId":"NCT04619004","phase":"PHASE2","title":"HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2021-02-02","conditions":"Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor","enrollment":277},{"nctId":"NCT04965766","phase":"PHASE2","title":"Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2021-05-11","conditions":"Metastatic Breast Cancer, Advanced Breast Cancer","enrollment":139},{"nctId":"NCT04676477","phase":"PHASE1","title":"HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2021-06-11","conditions":"Non-Small Cell Lung Cancer (NSCLC)","enrollment":246},{"nctId":"NCT05620914","phase":"PHASE2","title":"A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases","status":"WITHDRAWN","sponsor":"Mustafa Khasraw, MBChB, MD, FRCP, FRACP","startDate":"2025-07","conditions":"Brain Metastases, Adult","enrollment":""},{"nctId":"NCT06099639","phase":"","title":"Medical Access Program for Patritumab Deruxtecan","status":"NO_LONGER_AVAILABLE","sponsor":"Daiichi Sankyo","startDate":"","conditions":"Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer","enrollment":""},{"nctId":"NCT06222489","phase":"PHASE2","title":"Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2025-03-03","conditions":"Non-Small Cell Lung Carcinoma, Advanced Non-Small Cell Squamous Lung Cancer, EGFR Gene Mutation","enrollment":16},{"nctId":"NCT05338970","phase":"PHASE3","title":"HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2022-07-08","conditions":"Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion","enrollment":586},{"nctId":"NCT06298084","phase":"PHASE1, PHASE2","title":"Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2024-03-21","conditions":"Breast Cancer Metastatic, HER2-positive Metastatic Breast Cancer, HER2 Low Breast Carcinoma","enrollment":152},{"nctId":"NCT05569811","phase":"PHASE2","title":"NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"SOLTI Breast Cancer Research Group","startDate":"2022-11-25","conditions":"Breast Cancer","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":35,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["patritumab deruxtecan, U3-1402, MK-1022","patritumab deruxtecan","MK-1022","U3-1402","Patritumab deruxtecan"],"phase":"phase_2","status":"active","brandName":"HER3-DXd","genericName":"HER3-DXd","companyName":"Merck Sharp & Dohme LLC","companyId":"merck-sharp-dohme-llc","modality":"Biologic","firstApprovalDate":"","aiSummary":"HER3-DXd is a HER3-targeting antibody-drug conjugate. Used for Breast cancer, Gastric cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}